Inclusion Criteria:  Cohort A:  Age 18-75 years Histologically or cytologically confirmed adenocarcinoma of the prostate with very high risk for the development of metastases (defined as PSA ≥20 or Gleason Score ≥8 or ≥cT3) and/or oligometastatic (T any, N positive, M any or T any, N any, M positive) Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1 Planned radical prostatectomy ≤ 5 osseous metastasis Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures  Cohort B - mCRPC:  Age ≥ 18 years Histologically or cytologically confirmed prostate adenocarcinoma. Presence of skeletal or nodal metastases according to one of the following criteria: Confirmed pathological fracture related to the disease OR Confirmation of distant bone and/or nodal metastases on CT or MRI scan or bone scintigraphy.  OR  Positive pathology report of metastatic lesion. Disease progression despite ADT as indicated by: PSA increase that is ≥ 2 ng/mL and ≥ 25% above the minimum PSA as reached during ADT or above the pre-treatment level, if no response was observed and which is confirmed by a second value 1 or more weeks later.  OR  Progression of measurable lymph nodes (short axis ≥ 15 mm) or visceral lesion measurable per RECIST OR New metastatic lesions appearing on bone scan/imaging Chemical or surgical castration Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures  Cohort C:  Age ≥ 18 years Histologically or cytologically confirmed prostate adenocarcinoma. Planned radical prostatectomy Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures  Cohort D:  Age ≥ 18 years Histologically or cytologically confirmed bladder cancer. Planned radical cystectomy Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures  Exclusion Criteria:  Cohort A:  Tumour infiltration of the rectum or pelvic wall Visceral metastasis HIV positive Any contraindication for surgery Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures. Any contraindication for performing a PET/MRI scan (if applicable) Patient's not eligible for the size of the PET/MRI gantry  Cohort B - mCRPC:  HIV positive Any contraindication for tissue biopsy (if tissue biopsy is planned) Any contraindication for surgery (if surgery is planned) Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures. Any contraindication for performing a PET/MRI scan (if applicable) Patient's not eligible for the size of the PET/MRI gantry  Cohort C:  Any contraindication for surgery Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures. Any contraindication for performing a PET/MRI scan (if applicable) Patient's not eligible for the size of the PET/MRI gantry  Cohort D:  Any contraindication for surgery Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures. Any contraindication for performing a PET/MRI scan (if applicable) Patient's not eligible for the size of the PET/MRI gantry